CLIMB BIO INC宣布,其针对PMN(进行性多发性神经病)的Budoprutug Prismn二期临床试验已完成首例患者给药。该试验旨在评估候选药物的安全性与有效性,预计将于2026年下半年获得初步研究数据。这一里程碑标志着公司在神经疾病治疗领域的研发推进取得重要进展。
CLIMB BIO INC宣布,其针对PMN(进行性多发性神经病)的Budoprutug Prismn二期临床试验已完成首例患者给药。该试验旨在评估候选药物的安全性与有效性,预计将于2026年下半年获得初步研究数据。这一里程碑标志着公司在神经疾病治疗领域的研发推进取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.